Iambic Therapeutics Announces the Addition of Dr. Mary Tagliaferri to Its Board of Directors
Nektar Management to Present at Upcoming Investor Conferences
Nektar Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Nektar Therapeutics | 10-Q: Q2 2024 Earnings Report
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
Nektar Therapeutics Q2 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate, Sales $23.489M Beat $17.545M Estimate
Express News | Nektar Therapeutics: Cash & Marketable Securities Are Expected to Support Strategic Development Activities & Operations Into Q3 of 2026
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q2 Revenue $23.5M, Vs. Street Est of $17.6M
Express News | Nektar Therapeutics Reports Second Quarter 2024 Financial Results
Express News | Nektar Therapeutics Q2 Net Income USD -52.363 Million
Express News | Nektar Therapeutics Q2 Income From Operations USD -49.774 Million
Express News | Nektar Therapeutics Q2 Product Sales USD 6.64 Million
Express News | Nektar Therapeutics Q2 EPS USD -0.25
Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets
There's Reason For Concern Over Nektar Therapeutics' (NASDAQ:NKTR) Massive 26% Price Jump
Nektar Therapeutics' (NASDAQ:NKTR) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 13% Over the Past Week
Rodman & Renshaw Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $2
Rodman & Renshaw analyst Anthony Butler initiates coverage on $Nektar Therapeutics(NKTR.US)$ with a buy rating, and sets the target price at $2.According to TipRanks data, the analyst has a success ra
Oppenheimer Maintains Nektar Therapeutics(NKTR.US) With Hold Rating
Oppenheimer analyst Jay Olson maintains $Nektar Therapeutics(NKTR.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 43.6% and a total average return of 16.3% over t
Nektar Therapeutics(NKTR.US) Director Sells US$23,400 in Common Stock
$Nektar Therapeutics(NKTR.US)$ Director CHESS ROBERT sold 19,500 shares of common stock on Jun 14, 2024 at an average price of $1.2 for a total value of $23,400.Source: Announcement What is statement